Association Testing of Previously Reported Variants in a Large Case-Control Meta-analysis of Diabetic Nephropathy by Williams, Winfred W. et al.
 
Association Testing of Previously Reported Variants in a Large
Case-Control Meta-analysis of Diabetic Nephropathy
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Williams, W. W., R. M. Salem, A. J. McKnight, N. Sandholm,
C. Forsblom, A. Taylor, C. Guiducci, et al. 2012. “Association
Testing of Previously Reported Variants in a Large Case-
Control Meta-analysis of Diabetic Nephropathy.” Diabetes 61
(8): 2187-2194. doi:10.2337/db11-0751.
http://dx.doi.org/10.2337/db11-0751.
Published Version doi:10.2337/db11-0751
Accessed February 19, 2015 2:25:34 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11855856
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAAssociation Testing of Previously Reported Variants
in a Large Case-Control Meta-analysis
of Diabetic Nephropathy
Winfred W. Williams,
1,2,3,4 Rany M. Salem,
2,5 Amy Jayne McKnight,
6 Niina Sandholm,
7,8,9
Carol Forsblom,
7,8 Andrew Taylor,
1,2,10 Candace Guiducci,
2 Jarred B. McAteer,
1,2,10 Gareth J. McKay,
6
Tamara Isakova,
11 Eoin P. Brennan,
12,13 Denise M. Sadlier,
12,13,14 Cameron Palmer,
2,5
Jenny Söderlund,
7,8 Emma Fagerholm,
7,8 Valma Harjutsalo,
7,8,15 Raija Lithovius,
7,8 Daniel Gordin,
7,8
Kustaa Hietala,
7,16 Janne Kytö,
7,16 Maija Parkkonen,
7,8 Milla Rosengård-Bärlund,
7,8 Lena Thorn,
7,8
Anna Syreeni,
7,8 Nina Tolonen,
7,8 Markku Saraheimo,
7,8 Johan Wadén,
7,8 Janne Pitkäniemi,
17
Cinzia Sarti,
17 Jaakko Tuomilehto,
15,17,18 Karl Tryggvason,
19 Anne-May Österholm,
19 Bing He,
19
Steve Bain,
20 Finian Martin,
12,21 Catherine Godson,
12,13 Joel N. Hirschhorn,
2,5 Alexander P. Maxwell,
6
Per-Henrik Groop,
7,8 and Jose C. Florez,
1,2,4,10 for the GENIE Consortium
We formed the GEnetics of Nephropathy–an International Effort
(GENIE) consortium to examine previously reported genetic asso-
ciations with diabetic nephropathy (DN) in type 1 diabetes. GENIE
consists of 6,366 similarly ascertained participants of European
ancestry with type 1 diabetes, with and without DN, from the
All Ireland-Warren 3-Genetics of Kidneys in Diabetes U.K. and Re-
public of Ireland (U.K.-R.O.I.) collection and the Finnish Diabetic
Nephropathy Study (FinnDiane), combined with reanalyzed data
from the Genetics of Kidneys in Diabetes U.S. Study (U.S.
GoKinD). We found little evidence for the association of the
EPO promoter polymorphism, rs161740, with the combined phe-
notype of proliferative retinopathy and end-stage renal disease in
U.K.-R.O.I. (odds ratio [OR] 1.14, P = 0.19) or FinnDiane (OR 1.06,
P=0.60). However, a ﬁxed-effects meta-analysis that included the
previously reported cohorts retained a genome-wide signiﬁcant
association with that phenotype (OR 1.31, P=2 3 10
29). An
expanded investigation of the ELMO1 locus and genetic regions
reported to be associated with DN in the U.S. GoKinD yielded only
nominal statistical signiﬁcance for these loci. Finally, top candi-
dates identiﬁed in a recent meta-analysis failed to reach genome-
wide signiﬁcance. In conclusion, we were unable to replicate most
of the previously reported genetic associations for DN, and signif-
icance for the EPO promoter association was attenuated.
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T
ype 1 diabetes has continuously increased world-
wide, and the highest incidence is found in Finland
(1). Diabetic nephropathy (DN) is a complication
that develops in approximately 25–40% of patients
w i t ht y p e1a n dt y p e2d i a b e t e s. DN is the leading cause of
end-stage renal disease (ESRD) in the developed world.
Currently, 44% of the new cases of ESRD in the U.S. annually
are attributable to DN (2). A better understanding of the
causal factors of DN and its pathogenesis may lead to new
strategies to decrease its incidence, preemptively treat the
disorder, attenuate morbidity and mortality, and would be
a valuable contribution to global public health.
Several observations suggest that DN, one of the major
complications of type 1 and type 2 diabetes, has an in-
herent genetic susceptibility. Familial clustering of DN is
evident for both type 1 and type 2 diabetes (3–6), and ge-
netic risk factors are being sought in multiple populations
(7–9). Unfortunately, robust replication of many initial
associations has not been forthcoming (10).
This study recruited a large collection of individuals with
type 1 diabetes as part of the GEnetics of Nephropathy–an
International Effort (GENIE) consortium and examined se-
lected candidate loci associated with DN from genome-wide
case-control studies or other association studies that
reported high levels of statistical signiﬁcance. The variants
examined and the rationale for their inclusion are as follows:
1) A single nucleotide polymorphism (SNP) (rs1617640)
within the promoter region of the EPO gene (encoding
erythropoietin) was identiﬁed as having a genome-wide
signiﬁcant (P , 5 3 10
28) association with ESRD and
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ORIGINAL ARTICLEproliferative diabetic retinopathy (PDR) (11). Interest-
ingly, erythropoietin levels were elevated sevenfold
in the human vitreous ﬂuid of nondiabetic individuals
with the risk genotype TT compared with those with
the wild-type GG genotype. In addition, EPO expres-
sion levels were signiﬁcantly elevated above control in
the tissues and vitreous ﬂuid of animal models of DN
(DN in db/db mice) and in proliferative retinopathy
(murine oxygen-induced retinopathy model), respec-
tively (11).
2) The engulfment and cell motility 1 gene (ELMO1) has
been reported to be associated with DN in Japanese
patients with type 2 diabetes (12). Recently, Pezzolesi
et al. (13), using the Genetics of Kidneys in Diabetes
U.S. Study (U.S. GoKinD) cohorts, also examined
ELMO1 for association with DN and presented evi-
dence of association of variants within this gene for
the development of DN. However, the risk alleles for
ELMO1 identiﬁed in their study differed from those
reported in the original Japanese investigation. In the
context of a genome-wide association study (GWAS),
118 SNPs were assessed in 1,705 individuals of Euro-
pean ancestry with type 1 diabetes (885 control subjects
and 820 DN case subjects). The strongest associations
in ELMO1 in the U.S. study occurred at rs11769038
(odds ratio [OR] 1.24; P = 1.7 3 10
23) and rs1882080
(OR 1.23; P = 3.2 3 10
23), located in intron 16. Two
additional SNPs, located in introns 18 and 20, were
also nominally associated with DN. In total, eight
ELMO1 SNPs were reported to confer risk for DN, al-
though none reached genome-wide signiﬁcance (13).
Supportive evidence was also found in African Ameri-
cans with type 2 diabetes and ESRD (14).
3) The U.S. GoKinD GWAS analyzed 359,193 SNPs in 820
case subjects (284 with proteinuria and 536 with ESRD)
and 885 control subjects with type 1 diabetes but no
evidence of DN. Although no risk variant achieved
genome-wide signiﬁcance, the primary association anal-
ysis identiﬁed 11 SNPs representing four distinct chromo-
somal regions (P , 1 3 10
25). The strongest association
with DN reported in this study was on chromosome 9q
with rs10868025 (OR 1.45, P =5 . 03 10
27)( 1 5 ) .
4) Finally, in an effort to systematically explore and compre-
hensively capture common genetic variations that might
be associated with DN, we reviewed the largest meta-
analysis published to date studying genetic associations
with the DN phenotype (7). In GENIE, we examined the
top-reported SNP (or proxy) for each gene in that report
for an association with DN.
In this study, we have assembled the largest reported
case-control sample of DN in type 1 diabetes to evaluate
the previously reported genetic associations in newly geno-
typed samples from the U.K., Republic of Ireland (R.O.I.),
and Finland, plus pre-existing data from the U.S. GoKinD.
RESEARCH DESIGN AND METHODS
Cohorts
U.K.-R.O.I. collection. Recruited individuals were part of the All Ireland-
Warren 3-Genetics of Kidneys in Diabetes U.K. collection (U.K.-R.O.I.). All were
self-reported as white, with grandparents born in the U.K. or Ireland, and type 1
diabetes diagnosed before the age of 31 years requiring uninterrupted insulin
treatment. Case subjects (n = 903) with DN had persistent proteinuria (.0.5
g/24 h), hypertension (.135/85 mmHg and/or treatment with antihypertensive
medication), and diabetic retinopathy. ESRD (28%) was deﬁned as requiring
renal replacement therapy or having received a kidney transplant. Individuals
in the control group (n = 1,001) had had type 1 diabetes for at least 15 years,
had no evidence of microalbuminuria on repeated testing, and were not re-
ceiving antihypertensive medication (Table 1).
Finnish Diabetic Nephropathy Study (FinnDiane). The FinnDiane study
is a nationwide multicenter study of .4,800 adult participants with type 1
diabetes (16). This study comprises genotype data for 2,914 patients with type
1 diabetes diagnosed before age 35 years and insulin treatment started within
1 year of diagnosis. The disease status was deﬁned by urine albumin excretion
rate (AER) or urine albumin-to-creatinine ratio (ACR) in at least two of three
consecutive urine collections at local centers. Macroalbuminuria (n = 686)
was deﬁned as AER .200 mg/min or .300 mg/24 h or an ACR .25 mg/mmol
for men and .35 mg/mmol for women in overnight, 24-h, or spot urine col-
lections, respectively. Similarly, the limit for normal AER (n = 1,601) was ,20
mg/min or ,30 mg/24 h or ACR ,2.5 mg/mmol for men and ,3.5 mg/mmol for
women. Control patients with normal AER were required to have type 1
diabetes duration of at least 15 years. ESRD (n = 627) was deﬁned as ongoing
dialysis treatment or receipt of a kidney transplant. From the total, 505 par-
ticipants were included from an independent Finnish cohort collected by the
National Institute for Health and Welfare (17). These participants met the
FinnDiane diagnosis and selection criteria and were analyzed together with
the FinnDiane cohort (Table 1).
U.S. GoKinD. The U.S. GoKinD study consists of a DN case-control cohort of
individuals diagnosed with type 1 diabetes before age 31 years, who were
between 18 and 59 years of age at enrollment, and who began insulin treatment
within 1 year after diagnosis (18). The 905 case subjects were deﬁned as people
aged 18–54, with type 1 diabetes for at least 10 years, and DN. The 898 control
subjects were aged 18–59, had type 1 diabetes for at least 15 years, but did not
have DN. The DN deﬁnition includes individuals with ESRD (on dialysis or
having received a kidney transplant) or persistent macroalbuminuria (at least
two of three tests positive for albuminuria by dipstick $1+ or ACR .300 mg
albumin/mg of urine creatinine). The U.K. GoKinD inclusion criteria were used
to recruit individuals to the control group. Individuals were recruited at two
study centers, George Washington University (GWU) and the Joslin Diabetes
TABLE 1
Phenotypic characteristics of the GENIE cohorts (U.K.-R.O.I., FinnDiane, and U.S. GoKinD)
U.K.-R.O.I. FinnDiane U.S. GoKinD†
Case subjects Control subjects Case subjects Control subjects Case subjects Control subjects
n 903 1,001 1,289 1,577 774 821
Sex (n)
Male 531 438 764 651 402 342
Female 372 563 525 926 372 479
Type 1 diabetes
Duration (years) 32.9 6 9.5 27.2 6 8.7 32.8 6 9.1 27.9 6 9.5 31.4 6 7.8 25.4 6 7.7
Age at diagnosis (years) 14.6 6 7.7 14.5 6 7.8 12.8 6 7.6 15.1 6 8.3 11 6 6.6 13 6 7.3
HbA1c (%) 9.0 6 1.9 8.7 6 1.6 8.8 6 1.6 8.0 6 1.2 7.5 6 1.9 7.5 6 1.2
BMI (kg/m
2) 26.2 6 4.7 26.2 6 4.2 25.5 6 4.2 25.2 6 3.4 25.7 6 5.2 26.1 6 4.3
ESRD (%) 28.0 0 48.2 0 65.6 0
Categoric data are shown as indicated; continuous data as mean 6 SD. †Reanalysis of the U.S. GoKinD dataset using new quality control
ﬁlters to account for published plate effects (see RESEARCH DESIGN AND METHODS for complete details).
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Pezzolesi et al. [15] for details). Analysis of the U.S. GoKinD cohort was lim-
ited to individuals whose reported primary ethnicity was white.
Phenotype deﬁnition: DN and EPO study outcomes. DN was the primary
outcomeforallassociationstudies oftheSNPs investigated. Forthe EPOstudy,
we used the phenotypic deﬁnitions used in the original report (11); namely,
ESRD as deﬁned by case subjects who were on dialysis or who had received
a renal transplant; concurrently, this ESRD population also had to have evi-
dence of advanced PDR on physical examination and a history of laser
treatment. Control subjects with evidence of PDR were excluded. We also
examined PDR as an outcome independent of ESRD status. For this analysis,
case subjects had clinical evidence of PDR, whereas control subjects had none
(irrespective of DN status). Cohorts analyzed in the original EPO study (Fig. 1)
were composed of European-American cases, and control subjects were col-
lected from distinct geographic areas in the U.S. These included the GoKinD
cohort (Boston, Pittsburgh, and Minnesota), the Utah cohort (Salt Lake City),
and the Boston cohort (Boston Joslin Center for Diabetes) (11).
SNP selection. SNP markers with evidence for association with DN sus-
ceptibility in reference studies (11) were selected for genotyping in GENIE.
Where more than one SNP was associated at a particular locus with DN, the
most strongly associated variant was selected for genotyping in the DN
case-control cohorts. Where no genotyping assay could be developed for the
index SNP, a proxy in strong linkage disequilibrium (LD) was genotyped using
the CEU HapMap population. CEU is the ofﬁcial three letter code for the
HapMap samples of Utah residents with ancestry from Northern and Western
Europe (see http://hapmap.ncbi.nlm.nih.gov/citinghapmap.html). For the
original U.S. GoKinD reported results and ELMO1, additional SNPs within
20-kb upstream and downstream of the locus (or index SNP) were selected
using the SNP Annotation and Proxy Search (http://www.broadinstitute.org/
mpg/snap/), specifying chromosome position, CEU samples, and 1000 Genome
Pilot 1 data. The expanded SNP list was extracted from GWAS results for
U.K.-R.O.I. and FinnDiane (N. Sandholm et al., submitted).
De novo genotyping. For the U.K.-R.O.I. collection (n = 1,904 unique indi-
viduals), SNPs were genotyped using Sequenom iPLEX (Sequenom, Hamburg,
Germany) or TaqMan (Applied Biosystems, Warrington, U.K.) technology.
Duplicate and no-DNA-template samples were included on all plates as ex-
perimental controls.
In FinnDiane, the EPO locus was genotyped with TaqMan chemistry (Applied
Biosystems, Foster City, CA) in 3,363 samples, of which 251 case subjects
(ESRD + laser treatment) and 987 control subjects (no DN, no retinopathy)
passed the phenotype criteria. All other SNPs were genotyped at the Institute of
Molecular Medicine Finland (Helsinki, Finland) on the Illumina’sB e a d A r r a y
610Quad array. Illumina’s BeadStudio clustering algorithm was used to call
genotypes in FinnDiane. SNPs were ﬁltered for those with call rates .95%, minor
allele frequency (MAF) .1%, and test for Hardy Weinberg equilibrium (HWE;
P . 1 3 10
23). Sample ﬁlters included individual call rates .95% and no ﬁrst-
degree relatives and resulted in 1,289 case subjects and 1,577 control subjects.
Existing genotype datafortheU.S. GoKinD genotypedata weredownloaded
from dbGAP (phs000018.v2.p1, retrieved June 2010), containing genotype data
from the Affymetrix 500 K array (Affymetrix, Santa Clara, CA). The version 2
genotype data differed from the original U.S. GoKinD data, containing updated
and recalled genotype calls for a previously reported problematic plate (19),
and SNP call rate (.90%), MAF (.1%), and HWE performed by the National
Heart, Lung, and Blood Institute. We applied additional quality control (QC)
ﬁlters to the data, including removing samples with evidence of contamination
(extreme heterozygosity, n = 16), known parents (n = 4), non–European-
reported ancestry (n = 121), reported sex–genotype mismatch (n = 1), cryptic
related subjects (n = 4), and principal component analysis admixture outliers
(n = 5). Furthermore, SNP QC ﬁlters were applied to remove known prob-
lematic SNPs, HWE (P . 1 3 10
27), call rate (90%), missingness, MAF (1%),
and SNPs plate effects.
GWAS genotyping. Genotypes for U.K.-R.O.I. (n = 1,830) and FinnDiane
(n = 3,651) were supplemented with SNPs retrieved from GWAS results for
each study (Sandholm et al., submitted). The FinnDiane study samples were
genotyped using the Illumina’s BeadArray 610-Quad (Illumina, San Diego, CA)
array at the Institute of Molecular Medicine Finland (FIMM, Helsinki, Finland).
The U.K.-R.O.I. study samples were genotyped at the Broad Institute using the
Illumina Omni1-Quad array. Samples with insufﬁcient DNA quality, quantity,
or poor genotype concordance with previous available genotypes at a ﬁnger-
printing stage were excluded. For all three discovery datasets (FinnDiane,
U.K.-R.O.I., U.S. GoKinD), a standardized and detailed genotype QC proce-
dures were applied using PLINK supplemented with perl and R scripts. These
included selecting SNPs with a call rate .90%, MAF .1%, and concordance
with HWE (P . 10
27). We discarded samples with a call rate ,95%, extreme
heterozygosity, cryptic relatedness, or ethnic outliers by principal components
analysis, and tested for SNP missingness by haplotype (P , 10
28), by phenotype
(P . 10
28), and by plate effects (P , 10
27). Probes for copy number variation
as well as sex chromosome and mitochondrial SNPs were excluded from
analyses. After applying the QC protocol, we had access to 549,530 SNPs in
3,370 FinnDiane samples, 791,687 SNPs in 1,726 U.K.-R.O.I. samples, and
360,899 SNPs in 1,595 U.S. GoKinD samples.
SNP imputation. MACH 1.0 software (http://www.sph.umich.edu/csg/abecasis/
MACH) with the HapMap phase II CEU reference panel was used to perform
SNP imputation for GWAS results in each cohort. Estimates of the crossover
and error rates were obtained via 50 iteration rounds in ;300 randomly se-
lected samples per cohort. A greedy algorithm was used for imputation, and
the maximum likelihood method was speciﬁed to yield allele dosages. A ﬁlter
was applied to exclude SNPs with low imputation quality (r
2 , 0.6),
resulting in ;2.4 million SNPs per cohort.
Statistical analysis. Association tests were conducted using PLINK v1.07 (20)
(http://pngu.mgh.harvard.edu/purcell/plink), with logistic regression adjusted
for sex and age. U.K.-R.O.I. was adjusted for recruitment center, but the two U.S.
GoKinD centers, GWU and JDC, were analyzed separately as reported by
Pezzolesi et al. (15). Data from the GWAS genotyping was adjusted addition-
ally for duration of type 1 diabetes and principal components from Eigenstrat
analysis. The EPO locus was analyzed with the Pearson x
2 test in the Finn-
Diane dataset without adjusting for any covariates. Fixed-effects meta-analyses
were conducted with the software package Comprehensive Meta-Analysis
(Version 2.2.040, Englewood, NJ) and the software package METAL (http://
www.sph.umich.edu/csg/abecasis/Metal/) (21) under the additive genetic
model. To determine the appropriate statistical cutoff for correction for
multiple testing, we calculated the total number of effective tests (because
a large portion of SNPs were in LD), using SNPSpD (http://gump.qimr.edu.au/
general/daleN/SNPSpD/). SNPSpD uses correlation between analyzed SNPs to
calculate the total number of independent tests (22). The total number of SNPs
tested is 2,199, with 113.7 effect-independent tests. Thus the experiment-wide
cutoff for statistical signiﬁcance was set at 4.4 3 10
24 (0.05/113.7).
RESULTS
EPO promoter polymorphism. The association of the
EPO promoter polymorphism, rs1617640, with DN was
evaluated by de novo genotyping of the SNP in GENIE. For
this analysis, case subjects were deﬁned as having both
ESRD and PDR because the initial report showed the
polymorphism was robustly associated with DN when both
of these “extreme” phenotypes were coexpressed. Signiﬁcant
association was not observed in the U.K.-R.O.I. (P = 0.19)
or FinnDiane collections (P = 0.60), although the direc-
tions of effect were consistent with the original report.
Fixed-effects meta-analysis of the association of rs1617640
with ESRD/PDR, including the previously reported cohorts
(a total of 3,162 case and 3,845 control subjects across ﬁve
separate cohorts of European and European-American
ancestry) retained genome-wide statistical signiﬁcance
(OR 1.31 [95% CI 1.20–1.44], P =23 10
29; Fig. 1).
As an additional experimental control, we examined the
potential association of the EPO promoter polymorphism
with the development of PDR in case subjects, irrespective
of ESRD status. No association was observed between
EPO and PDR for the individual cohorts or in the meta-
analysis of the combined results for FinnDiane (OR 0.95
[95% CI 0.85–1.04], P = 0.25) or and U.K.-R.O.I. (0.96 [0.88–
1.04], P = 0.29). Furthermore, no association was observed
after inclusion of the restricted phenotype, PDR, in U.S.
GoKinD case and control subjects, separately, or in the
meta-analysis of all cohorts combined (results not shown).
ELMO1. Neither single-center nor meta-analysis of de novo
genotyping in U.K.-R.O.I., nor GWAS data for FinnDiane,
revealed a signiﬁcant association in subjects with type 1
diabetes between rs741301, the previously reported risk
variant within ELMO1, and DN (OR 1.04 [95% CI 0.95–1.13],
P=0.46; Supplementary Fig. 1). Pezzolesi et al. (13) also
tested rs741301 but did not replicate the reported associa-
tion. They went on to test other SNPs in the region and
reported nominal associations (P =0 . 0 0 2 –0.05) with eight
other SNPs . We examined LD between rs741301 and the
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tigators. The r
2 statistic between rs741301 and the other
SNPs revealed only low to moderate LD, ranging from 0.38
to 0.65 (Supplementary Table 1).
As an additional and more extensive test of variants in
this region, we performed an expanded analysis capturing
all available SNPs 20 kb upstream and downstream of the
ELMO1 locus to account for LD differences presumably
due to ancestry. Results of the expanded analysis did not
reveal any signiﬁcant SNPs for either cohort individually
or for the two cohorts meta-analyzed after correcting for
multiple testing (P , 4.3 3 10
24). Furthermore, no SNP
achieved signiﬁcance with inclusion of the U.S. GoKinD
results in the meta-analysis (Supplementary Table 2).
Risk variants reported from U.S. GoKinD for DN in
type 1 diabetes. Eleven DN susceptibility SNPs that were
ﬁrst reported by the U.S. GoKinD investigators as highly
associated with the risk of developing DN in type 1 di-
abetes were parsed into eight candidate loci. We selected
one representative SNP for each region of strong LD in
which multiple SNPs represented the same association
signal. After performing additional QC checks (see RESEARCH
DESIGN AND METHODS), we ﬁrst tested the eight U.S. GoKinD
potential DN susceptibility SNPs by reanalyzing the U.S.
GoKinD dataset downloaded from dbGAP (19). As in the
original report, none of the eight SNPs were associated
with DN at genome-wide statistical signiﬁcance (Table 2).
The two SNPs in the FERM (F [Band 4.1], E [Ezrin], R
[Radixin], M [Moesin]) domain 3 (FRMD3) region showed
similar P values as in the original report (2.1 3 10
27 and
1.6 3 10
26, respectively; Table 2). In our analysis, the
statistical signiﬁcance of the P values for SNPs in the
CPVL/CHN2 and CARS regions was reduced from 6.5 3
10
27 to 2 3 10
23 and 6.4 3 10
26 to 2.2 3 10
23, respectively.
P values for the 6 SNPs in the 13q region were also
changed from 1.8–7.0 3 10
26 to 1.4–9.5 3 10
25.
We next examined these SNPs in our newly genotyped
samples. Case-control association analysis for these loci in
the U.K.-R.O.I. and FinnDiane samples revealed no signiﬁ-
cant associations in either cohort. The strongest signal was
observed at rs39075 near CPVL/CHN2 in U.K.-R.O.I., (OR
1.12, P = 0.08) and in meta-analysis of the two replication
cohorts (U.K.-R.O.I. and FinnDiane; OR 1.06, P = 0.06;
Table 2). In expanded locus-region analyses (plus or minus
20 kb of the locus of interest), no SNP reached signiﬁcance
after adjustment for multiple testing (one-tailed P = 0.03,
experiment-wide threshold P = 4.3 3 10
24) for the two
cohorts separately or via meta-analysis. The combined
meta-analysis including U.S. GoKinD revealed two SNPs
downstream of FRMD3, rs1888747 (P = 1.5 3 10
24) and
rs13288659 (P = 9.7 3 10
25), which showed signiﬁcance
after adjusting for experiment-wide multiple testing (P ,
4.3 3 10
24). However, neither SNP achieved genome-wide
signiﬁcance (P , 5 3 10
28; Supplementary Table 3).
Pooled meta-analyses examining variants associated
with DN in type 1 and type 2 diabetes. In the most
comprehensive literature search for DN associated genetic
variants to date, Mooyaart et al. (7) identiﬁed 24 loci. In
GENIE, we examined all the available top-reported SNPs
(or their proxies) for each gene in that report. Three SNPs
were nominally associated (P , 0.05) with DN: rs13293564
at UNC13B (P = 0.01) and rs179975 at the ACE (P=0.03)
in FinnDiane, and rs39075 at CPVL/CHN2 (P=0.05) in the
U.K.-R.O.I. samples. In a meta-analysis of the two cohorts,
the ACE polymorphism remained nominally signiﬁcant
(P=0.04). Including the U.S. GoKinD results, the FRMD3
signal at rs1888747 emerged as noted above; no other
signals were signiﬁcant after adjusting for multiple com-
parisons (see Supplementary Table 4 for full details).
DISCUSSION
Using a large, homogeneous population sample of European
ancestry subjects with type 1 diabetes in the GENIE con-
sortium, we were unable to replicate most of the previously
reported genetic associations with DN that we examined.
Our ﬁndings do not support previously reported genetic
associations with DN in type 1 diabetes in the largest GWAS
published to date (15). None of those signals reached
genome-wide statistical signiﬁcance with the addition of
larger, similarly ascertained datasets. Using ORs at the
lower limit of the 95% CI from the original publication, our
FIG. 1. Previously published and new results from this study provide an estimate of the effect of the EPO promoter SNP (rs1617640) on the risk of the
combined phenotype of PDR and ESRD in type 1 diabetes in ﬁve cohorts (3,162 case subjects and 3,845 control subjects) in a ﬁxed-effects meta-analysis.
PRIOR GENETIC ASSOCIATIONS WITH DN
2190 DIABETES, VOL. 61, AUGUST 2012 diabetes.diabetesjournals.orgcombined sample of U.K.-R.O.I. and FinnDiane cohorts in
GENIE had 99.9% power (at a = 0.001) to detect the U.S.
GoKinD reported effect sizes (Supplementary Table 5);
thus, our negative results (even at a = 0.05) were un-
expected. Further, after performing additional QC checks
on the original U.S. GoKinD dataset and combining these
samples with GENIE, we were unable to achieve genome-
wide signiﬁcant replication in the meta-analysis.
We investigated other previously reported genetic asso-
ciations with DN in subjects with type 1 diabetes, namely
the EPO promoter polymorphism rs1617640 and variants
within the ELMO1 gene; these also failed to replicate in
GENIE. The EPO promoter polymorphism retained genome-
wide signiﬁcance after meta-analysis of the prior data
combined with ours, for the combined phenotype of ESRD
and PDR. However, the overall P value attained was at-
tenuated from 2.8 3 10
211 to 2 3 10
29.
We also did not observe evidence for replication of the
association of rs741301 in the ELMO1 gene and DN in
GENIE. Shimazaki et al. (12) ﬁrst reported an association
for this genetic variant with DN in Japanese subjects with
type 2 diabetes. Subsequently, Pezzolesi et al. (13) failed to
replicate the association of the same SNP in type 1 diabetes
but reported that eight SNPs within the gene locus had
nominal associations with DN in the European-derived
subjects in U.S. GoKinD. Lack of replication may be due to
different genomic patterns in populations of diverse ances-
tries or the distinct genetic architecture of DN in type 1
versus type 2 diabetes (14). To address the ﬁrst concern,
we expanded our analysis by interrogating all available
SNPs plus or minus 20 kb of ELMO1. Because in the U.S.
GoKinD analysis of ELMO1 the risk variants were only in
weak to modest LD with the index SNP (r
2 between
rs741301 and the U.S. GoKinD SNPs ranged from 0.38 to
0.65), we reasoned that this expanded strategy would ac-
count for most of the differences in LD presumably due to
ancestry. The results of this expanded analysis, however,
did not reveal any signiﬁcant association for the additional
670 SNPs interrogated in ELMO1 in the U.K.-R.O.I. or
FinnDiane cohorts individually, for these two cohorts in
meta-analysis, or when combined with previously reported
risk variants reported from U.S. GoKinD.
As a ﬁnal step to ensure a systematic and more com-
prehensive approach to candidate loci associated with DN,
we reviewed the top SNPs from the 24 loci cited by the
largest meta-analysis published to date that has examined
candidate genetic variants for association with DN (7). From
the results of the pooled meta-analyses, the strongest signal
emerged at rs1888747 in FRMD3 (P =1 . 53 10
24). Variants
within this gene have been reported to be associated with
DN in European cohorts (7,15,23), and Freedman et al.
(24) recently reported evidence for a role for gene–gene
interactions between myosin heavy-chain 9 (MYH9)–
apolipoprotein L1 (APOL1) haplotypes and FRMD3 in
African American subjects. It should be noted, however,
that risk variants within this gene have achieved only
nominal but not genome-wide statistical signiﬁcance in all
previous reports.
From the foregoing observations, we conclude that
there is a high likelihood that many of the previously
reported positive associations with DN represent potential
false-positive ﬁndings (type I error). We emphasize that the
combined sample of U.K.-R.O.I. and FinnDiane represents
a substantially larger collection of case and control subjects
than U.S. GoKinD and is well powered to detect the origi-
nally reported effect sizes, thereby decreasing the likelihood
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for the likely overestimation of effect sizes due to the
winner’s curse phenomenon (25). We also harmonized the
ascertainment criteria for case-control deﬁnitions across
all the study populations (including U.S. GoKinD), making
it unlikely that phenotypic heterogeneity across study
populations explains the lack of replication.
A crucial issue that bears on the interpretation of
case-control studies of the genetics of DN concerns the
adequacy of phenotype deﬁnition. In this and most studies
cited to date, there is the presumption that long-duration
diabetes exposure and the presence of frank protein in the
urine—macroalbuminuria—deﬁnes DN and that pheno-
typic heterogeneity has been well controlled through this
classiﬁcation. These deﬁnitions are derived in large mea-
sure from the classic studies of Parving et al. (26), Viberti
et al. (27), and Mogensen and Christensen (28), who docu-
mented 30 years ago a virtually inexorable progression to
ESRD in patients who developed microalbuminuria after
approximately 2 decades of exposure to the diabetic met-
abolic milieu. However, these longitudinal ﬁndings were
based on small numbers of patients. The plasticity of DN
phenotypes is reﬂected in more recent and much larger
longitudinal studies showing that most patients with type 1
diabetes, categorized initially as having microalbuminuria,
undergo regression to normoalbuminuria with preservation
of renal function (29). It is not entirely clear that micro-
albuminuria versus macroalbuminuria, stage of chronic
kidney disease and attendant renal function, the rate of
renal decline, or the occurrence of extreme phenotypes,
such as ESRD/PDR, represent one disease process along
a continuum or many distinct disease states, each of which
may be under distinct genetic control. As pointed out re-
cently (24), genetic variants, such as those in MYH9 and
APOL1 that are common in certain ethnic groups, may
mask the effects at other loci unless methods such as
multilocus modeling and interaction analyses are used to
control for these effects.
In addition, phenotypic variation may be a function of
ethnicity and disease-speciﬁc gene expression. For exam-
ple, Pima Indians with type 2 diabetes have very early-
onset DN, characterized by an accelerated loss of renal
function and progression to ESRD despite lower blood
pressures and lipid levels, factors thought to be protective
(30). This has been postulated to be due to structural dif-
ferences in the nephron–podocyte number and density per
glomerulus (“podocyte insufﬁciency”), a decrease in net
nephron mass (glomerulopenia) resulting in glomerulomegaly,
increased intraglomerular capillary pressure, and ultimately,
hyperﬁltration injury (30). Whether these structural and
intrarenal hydraulic changes could be genetically regulated
is ultimately a testable hypothesis; they warrant further in-
vestigation to continue the inquiry why certain populations
have an apparent disproportional susceptibility to ESRD
and, particularly, DN.
In summary, we have presented evidence that several
previously reported genetic associations with DN in type 1
diabetes could not be replicated in a large, homogeneous
sample of subjects with type 1 diabetes. Our failure to
replicate these associations underscores the need to apply
stringent statistical thresholds of signiﬁcance, maximize
power through meta-analysis of all available data, and seek
replication in independent samples, as has been proposed
by a number of different authors (31,32). Finally, the ap-
plicability and generalizability of DN risk loci from type 1
diabetes to type 2 diabetes, and the related question of
shared genetic susceptibility for nephropathy between
type 1 and type 2 diabetes, remain unresolved.
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Health Centre: A. Mäkelä and P. Eloranta. Länsi-Uusimaa
Hospital, Tammisaari: I.-M. Jousmaa and J. Rinne. Malmi
Hospital, Helsinki: H. Lanki, S. Moilanen, and M. Tilly-Kiesi.
Mikkeli Central Hospital: A. Gynther, R. Manninen,
P. Nironen, M. Salminen, and T. Vänttinen. Mänttä Regional
Hospital: I. Pirttiniemi and A.-M. Hänninen. North Karelian
Hospital, Joensuu: U.-M. Henttula, P. Kekäläinen, M. Pietarinen,
A. Rissanen, and M. Voutilainen. Nurmijärvi Health Centre:
A. Burgos and K. Urtamo. Oulaskangas Hospital, Oulainen:
E. Jokelainen, P.-L. Jylkkä, E. Kaarlela, and J. Vuolaspuro.
Oulu Health Centre: L. Hiltunen, R. Häkkinen, and
S. Keinänen-Kiukaanniemi. Oulu University Hospital:
R. Ikäheimo. Päijät-Häme Central Hospital: H. Haapamäki,
A. Helanterä, S. Hämäläinen, V. Ilvesmäki, and H. Miettinen.
Palokka Health Centre: P. Sopanen and L. Welling. Pieksämäki
Hospital: V. Javtsenko and M. Tamminen. Pietarsaari Hospi-
tal: M.-L. Holmbäck, B. Isomaa, and L. Sarelin. Pori City
Hospital: P. Ahonen, P. Merensalo, and K. Sävelä. Porvoo
Hospital: M. Kallio, B. Rask, and S. Rämö. Raahe Hospital:
A. Holma, M. Honkala, A. Tuomivaara, and R. Vainionpää.
Rauma Hospital: K. Laine, K. Saarinen, and T. Salminen.
Riihimäki Hospital: P. Aalto, E. Immonen, and L. Juurinen.
Salo Hospital: A. Alanko, J. Lapinleimu, P. Rautio, and
M. Virtanen. Satakunta Central Hospital, Pori: M. Asola,
M. Juhola, P. Kunelius, M.-L. Lahdenmäki, P. Pääkkönen,
and M. Rautavirta. Savonlinna Central Hospital: E. Korpi-
Hyövälti, T. Latvala, and E. Leijala. South Karelia Central
Hospital, Lappeenranta: T. Ensala, E. Hussi, R. Härkönen,
U. Nyholm, and J. Toivanen. Tampere Health Centre:
A. Vaden, P. Alarotu, E. Kujansuu, H. Kirkkopelto-Jokinen,
M. Helin, S. Gummerus, L. Calonius, T. Niskanen, T. Kaitala,
and T. Vatanen. Tampere University Hospital: I. Ala-Houhala,
T. Kuningas, P. Lampinen, M. Määttä, H. Oksala, T. Oksanen,
K. Salonen, H. Tauriainen, and S. Tulokas. Tiirismaa Health
Centre, Hollola: T. Kivelä, L. Petlin, and L. Savolainen.
Turku Health Centre: I. Hämäläinen, H. Virtamo, and
M. Vähätalo. Turku University Central Hospital: K. Breitholz,
R .E s k o l a ,K .M e t s ä r i n n e ,U .P i e t i l ä ,P .S a a r i n e n ,R .T u o m i n e n ,
and S. Äyräpää. Vaajakoski Health Centre: K. Mäkinen and
P. Sopanen. Valkeakoski Regional Hospital: S. Ojanen,
E. Valtonen, H. Ylönen, M. Rautiainen, and T. Immonen.
Vammala Regional Hospital: I. Isomäki, R. Kroneld, and
M. Tapiolinna-Mäkelä. Vaasa Central Hospital: S. Bergkulla,
U. Hautamäki, V.-A. Myllyniemi, and I. Rusk.
REFERENCES
1. DIAMOND Project Group. Incidence and trends of childhood Type 1 di-
abetes worldwide 1990–1999. Diabet Med 2006;23:857–866
2. U.S. Renal Data System. USRDS 2010 Annual Data Report: Atlas of
Chronic Kidney Disease and End-Stage Renal Disease in the United
States. Bethesda, MD, National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases, 2010
3. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic
kidney disease. Evidence for genetic susceptibility to diabetic nephropa-
thy. N Engl J Med 1989;320:1161–1165
4. Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors de-
termine the development of diabetic nephropathy in patients with IDDM.
Diabetologia 1996;39:940–945
5. Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J. Population-based
assessment of familial clustering of diabetic nephropathy in type 1 diabetes.
Diabetes 2004;53:2449–2454
6. McKnight AJ, Currie D, Maxwell AP. Unravelling the genetic basis of renal
diseases; from single gene to multifactorial disorders. J Pathol 2010;220:
198–216
7. Mooyaart AL, Valk EJ, van Es LA, et al. Genetic associations in diabetic
nephropathy: a meta-analysis. Diabetologia 2011;54:544–553
8. Maeda S, Osawa N, Hayashi T, Tsukada S, Kobayashi M, Kikkawa R. Ge-
netic variations associated with diabetic nephropathy and type II diabetes
in a Japanese population. Kidney Int Suppl 2007:S43–S48
9. Nelson RG, Newman JM, Knowler WC, et al. Incidence of end-stage renal
disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima In-
dians. Diabetologia 1988;31:730–736
10. Conway BR, Maxwell AP. Genetics of diabetic nephropathy: are there
clues to the understanding of common kidney diseases? Nephron Clin
Pract 2009;112:c213–c221
11. Tong Z, Yang Z, Patel S, et al.; Genetics of Diabetes and Diabetic Com-
plication Study Group. Promoter polymorphism of the erythropoietin gene
in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA
2008;105:6998–7003
12. Shimazaki A, Kawamura Y, Kanazawa A, et al. Genetic variations in the
gene encoding ELMO1 are associated with susceptibility to diabetic ne-
phropathy. Diabetes 2005;54:1171–1178
13. Pezzolesi MG, Katavetin P, Kure M, et al. Conﬁrmation of genetic as-
sociations at ELMO1 in the GoKinD collection supports its role as
a susceptibility gene in diabetic nephropathy. Diabetes 2009;58:2698–
2702
W.W. WILLIAMS AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 61, AUGUST 2012 219314. Leak TS, Perlegas PS, Smith SG, et al. Variants in intron 13 of the ELMO1
gene are associated with diabetic nephropathy in African Americans. Ann
Hum Genet 2009;73:152–159
15. Pezzolesi MG, Poznik GD, Mychaleckyj JC, et al; DCCT/EDIC Research
Group. Genome-wide association scan for diabetic nephropathy suscepti-
bility genes in type 1 diabetes. Diabetes 2009;58:1403–1410
16. Thorn LM, Forsblom C, Fagerudd J, et al.; FinnDiane Study Group. Metabolic
syndrome in type 1 diabetes: association with diabetic nephropathy and
glycemic control (the FinnDiane study). Diabetes Care 2005;28:2019–2024
17. Osterholm AM, He B, Pitkaniemi J, et al. Genome-wide scan for type 1
diabetic nephropathy in the Finnish population reveals suggestive linkage
to a single locus on chromosome 3q. Kidney Int 2007;71:140–145
18. Mueller PW, Rogus JJ, Cleary PA, et al. Genetics of Kidneys in Diabetes
(GoKinD) study: a genetics collection available for identifying genetic
susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc
Nephrol 2006;17:1782–1790
19. Pluzhnikov A, Below JE, Konkashbaev A, et al. Spoiling the whole bunch:
quality control aimed at preserving the integrity of high-throughput geno-
typing. Am J Hum Genet 2010;87:123–128
20. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum
Genet 2007;81:559–575
21. Willer CJ, Li Y, Abecasis GR. METAL: fast and efﬁcient meta-analysis of
genomewide association scans. Bioinformatics 2010;26:2190–2191
22. Nyholt DR. A simple correction for multiple testing for single-nucleotide
polymorphisms in linkage disequilibrium with each other. Am J Hum
Genet 2004;74:765–769
23. Maeda S, Araki S, Babazono T, et al. Replication study for the association
between four Loci identiﬁed by a genome-wide association study on European
American subjects with type 1 diabetes and susceptibility to diabetic ne-
phropathy in Japanese subjects with type 2 diabetes. Diabetes 2010;59:
2075–2079
24. Freedman BI, Langefeld CD, Lu L, et al. Differential effects of MYH9 and
APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African
Americans. PLoS Genet 2011;7:e1002150
25. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-
analysis of genetic association studies supports a contribution of common
variants to susceptibility to common disease. Nat Genet 2003;33:177–182
26. Parving HH, Oxenbøll B, Svendsen PA, Christiansen JS, Andersen AR.
Early detection of patients at risk of developing diabetic nephropathy.
A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh)
1982;100:550–555
27. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Mi-
croalbuminuria as a predictor of clinical nephropathy in insulin-dependent
diabetes mellitus. Lancet 1982;1:1430–1432
28. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-
dependent patients. N Engl J Med 1984;311:89–93
29. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH,
Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl
J Med 2003;348:2285–2293
30. Lemley KV. A basis for accelerated progression of diabetic nephropathy in
Pima Indians. Kidney Int Suppl 2003;S38–S42
31. Chanock SJ, Manolio T, Boehnke M, et al.; NCI-NHGRI Working Group on
Replication in Association Studies. Replicating genotype-phenotype asso-
ciations. Nature 2007;447:655–660
32. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association
studies for complex traits: consensus, uncertainty and challenges. Nat Rev
Genet 2008;9:356–369
PRIOR GENETIC ASSOCIATIONS WITH DN
2194 DIABETES, VOL. 61, AUGUST 2012 diabetes.diabetesjournals.org